Jacobsen Capital Management Has $283,000 Stake in Amgen Inc. $AMGN

Jacobsen Capital Management boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 18.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,013 shares of the medical research company’s stock after buying an additional 161 shares during the quarter. Jacobsen Capital Management’s holdings in Amgen were worth $283,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in AMGN. Brighton Jones LLC boosted its holdings in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the last quarter. GAMMA Investing LLC raised its holdings in Amgen by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 11,753 shares of the medical research company’s stock worth $3,662,000 after purchasing an additional 3,369 shares during the last quarter. Flagship Harbor Advisors LLC lifted its position in shares of Amgen by 4.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 3,078 shares of the medical research company’s stock worth $959,000 after purchasing an additional 124 shares during the period. JFS Wealth Advisors LLC boosted its stake in shares of Amgen by 10.3% in the 1st quarter. JFS Wealth Advisors LLC now owns 992 shares of the medical research company’s stock valued at $309,000 after purchasing an additional 93 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new stake in shares of Amgen during the first quarter worth $276,000. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of several recent analyst reports. Piper Sandler boosted their target price on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a report on Monday, August 25th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $305.00 price target on shares of Amgen in a research note on Tuesday, June 24th. Raymond James Financial initiated coverage on Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Finally, Bank of America raised their price objective on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Six analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $300.94.

Amgen Trading Down 0.7%

AMGN opened at $301.14 on Wednesday. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $335.88. The firm has a market capitalization of $162.12 billion, a PE ratio of 24.62, a P/E/G ratio of 2.68 and a beta of 0.49. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The company’s 50-day moving average is $287.83 and its 200 day moving average is $287.15.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the company posted $4.97 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were paid a $2.38 dividend. The ex-dividend date was Friday, August 22nd. This represents a $9.52 annualized dividend and a dividend yield of 3.2%. Amgen’s dividend payout ratio is presently 77.84%.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.69% of the stock is currently owned by corporate insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.